MGC Pharmaceuticals Ltd. announced the grant of a Patent for the company's Investigational Medical Product, CimetrATM, from the Slovenian Intellectual Property Office (SIPO). The Patent: The grant of the Patent provides MGC Pharma commercial protection over the intellectual property associated with CimetrATM's unique formation and manufacturing process for a period of 20 years. CimetrATM is a nano-micellular pharmaceutical synergetic composition consisting of Curcumin, Boswellia and optionally, Artemisinin, Cannabinoids and/or Nitroxides.

The composition can be manufactured in liquid or solid pharmaceutically acceptable carriers, and has antioxidant, anti-inflammatory and immuno-modulating properties, and is designed for multiple therapeutic applications utilising Graft Polymer's GraftBioTM self-nanoemulsifying drug delivery system (SNEDDS). The Patent sets out the specific antioxidant, anti-inflammatory, and immune-modulating properties of CimetrATM, which is designed for multiple therapeutic applications including the prevention of systemic chronic inflammation, including the treatment and alleviation of the Cytokine Storm, a symptom of an infection of severe acute respiratory syndrome coronavirus 2 (the cause of COVID- 19) and heavy variants of influenza, as well as various types of cancer. This is in addition to its potential efficacy in relation to the regulation of the human body's circadian rhythm and homeostasis which promotes an immune response to bacterial, viral, fungal, and parasitic infections.

It's wide range of uses as a treatment highlights its versatility as an IMP.